Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

06. November 2023 16:01 ET | Quelle: Indaptus Therapeutics

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023...
06. November 2023 09:18 ET | Quelle: Research and Markets

Global Automotive Optoelectronics Market Set to Surge, Projected to Reach $55.82 Billion by 2028: Driven by Safety, Energy Efficiency, and Advanced Driving Technologies

Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Automotive Optoelectronics Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028" report has been added to ...
06. November 2023 08:01 ET | Quelle: Portage Biotech Inc.

Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Updated data support the proof of concept of using an iNKT engager monotherapy (PORT-2) to induce immune response for patients with non-small cell lung cancer (NSCLC) and melanomaStrong academic...
06. November 2023 08:00 ET | Quelle: Immutep Limited

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Media Release No safety or tolerability issues in open-label, safety lead-in phase evaluating the higher 90mg dose of efti in combination with weekly paclitaxel in the first 6 patients Good safety...
06. November 2023 08:00 ET | Quelle: Indaptus Therapeutics

Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform to...
06. November 2023 07:58 ET | Quelle: Research and Markets

Global Private Tutoring Market Soars to $177.2 Billion by 2028, Fueled by Rapid Urbanization and the Surge in Online Learning

Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "Private Tutoring Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ...
06. November 2023 07:30 ET | Quelle: InflaRx N.V.

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S.PG is a rare and debilitating autoimmune skin...
06. November 2023 07:26 ET | Quelle: Emergen Research

Global Artificial Intelligence in the Education Sector Market to Reach Value of USD 109.63 Billion by 2032 | Emergen Research

Vancouver, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The global artificial intelligence in the education sector market is forecast to reach a market size of USD 109.63 Billion by 2032 and register a...
06. November 2023 07:05 ET | Quelle: ZyVersa Therapeutics

ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation

Air pollution linked with development and progression of chronic kidney disease that can be attenuated by inhibiting inflammasome NLRP3 activation.
06. November 2023 07:00 ET | Quelle: EvolveImmune

EvolveImmune Therapeutics Presents New Preclinical and Translational Data on Novel CD2 Costimulatory T Cell Engager Platform at 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

BRANFORD, Conn., Nov. 06, 2023 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, an immuno-oncology company developing first-in-category, multifunctional biotherapeutics to overcome the therapeutic...

Vorherige Seite

Nächste Seite